When did Alnylam Pharmaceuticals report Q4 2024 earnings?

Alnylam Pharmaceuticals (ALNY) reported Q4 2024 earnings on February 13, 2025 before market open.

What were Alnylam Pharmaceuticals's Q4 2024 revenue and EPS?

Alnylam Pharmaceuticals reported revenue of $593.2M and diluted EPS of $0.06 for Q4 2024.

Did Alnylam Pharmaceuticals beat estimates in Q4 2024?

Revenue beat the consensus estimate of $582.6M by $10.6M. EPS beat the consensus estimate of $-0.62 by $0.68.

Where can I find Alnylam Pharmaceuticals's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001178670-25-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.

Alnylam Pharmaceuticals ALNY Q4 2024 Annual earnings

Reported February 13, 2025 · Before market open

Revenue$593.2MBeat by $10.6M Diluted EPS$0.06Beat by $0.68

Revenue estimate$582.6M

EPS estimate-$0.62

Next report

Jul 30, 2026 (In 2 weeks)

Revenue estimate$1.3B

EPS estimate$1.61

Financials

Q4 2024

Income statement

See full

Revenue$593.2M+34.9%

Gross profit$490.5M+33.4%

Operating income-$105.2M+9.7%

Net income-$83.8M+39.2%

EPS (diluted)-$0.65+40.4%

Balance sheet

See full

Cash & equivalents$968.7M+18.9%

Total debt$271.4M-4.6%

Total equity$67.1M+130%

Total assets$4.2B+10.7%

Cash flow

See full

Operating cash flow-$94.7M—

CapEx$9.1M-40.6%

Free cash flow-$103.8M—

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$30.35B+26.4%

Enterprise value$29.65B+26.2%

P/S13.5×+0.4×

Profitability

See full

Gross margin86.4%+1.0pp

Operating margin-7.9%-2.6pp

Net margin-12.4%-4.0pp

FCF margin-1.9%—

Returns & leverage

See full

Debt / equity4×—

Current ratio2.8×-0.3×

Versus estimates

Revenue

Q1 2026$1.2BBeat by $51.7M Q4 2025$1.1BMiss by $52.1M Q3 2025$1.2BBeat by $289.6M Q2 2025$773.7MBeat by $110.8M Q1 2025$594.2MBeat by $9.0M

Q4 2024$593.2MBeat by $10.6M

Diluted EPS

Q1 2026$1.51Beat by $0.64 Q4 2025$0.82Miss by $0.34 Q3 2025$2.90Beat by $2.34 Q2 2025$0.32Beat by $0.86 Q1 2025-$0.01Beat by $0.88

Q4 2024$0.06Beat by $0.68

Ask the moment Alnylam Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Alnylam Pharmaceuticals report Q4 2024 earnings?: Alnylam Pharmaceuticals (ALNY) reported Q4 2024 earnings on February 13, 2025 before market open.
What were Alnylam Pharmaceuticals's Q4 2024 revenue and EPS?: Alnylam Pharmaceuticals reported revenue of $593.2M and diluted EPS of $0.06 for Q4 2024.
Did Alnylam Pharmaceuticals beat estimates in Q4 2024?: Revenue beat the consensus estimate of $582.6M by $10.6M. EPS beat the consensus estimate of $-0.62 by $0.68.
Where can I find Alnylam Pharmaceuticals's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001178670-25-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.